[Experimental synthetic compound] MYCO-001
The Investigator Initiated trial is funded by a near $4 million grant from the National Institutes of Health, making this the first time in 50 years the U.S. government has funded a study evaluating a psychedelic compound for therapeutic use.
The recently cleared grant-funded trial is led by Principal Investigator (PI) Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University.
Original Article (Mydecine):
U.S. FDA clears MYCO-001 for multi-site government funded trial in smoking cessation
Artwork Fair Use: Iqbal Osman1